|
Hepatolenticular Degeneration
|
0.010 |
Biomarker
|
disease |
BEFREE |
ACP Best Practice No 163. Wilson's disease: acute and presymptomatic laboratory diagnosis and monitoring.
|
11127261 |
2000 |
|
Recurrent Chronic Lymphoid Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
|
26641137 |
2016 |
|
Neoplasms, Intracranial
|
0.010 |
Biomarker
|
group |
BEFREE |
Activating mutations in the gene encoding β-catenin have been identified in the paediatric form of human craniopharyngioma (adamantinomatous craniopharyngioma, ACP), a histologically benign but aggressive pituitary tumour accounting for up to 10% of paediatric intracranial tumours.
|
22349813 |
2012 |
|
Hemolytic reaction
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
An association between favism (a hemolytic reaction to consumption of fava beans), glucose-6-phosphate dehydrogenase deficiency (G6PD(-)) and acid phosphatase locus 1 (ACP(1)) phenotypes has been reported; the frequency of carriers of the p(a) and p(c) ACP(1) alleles was found to be significantly higher in G6PD(-) individuals showing favism than in the general population.
|
21644204 |
2011 |
|
Deficiency of glucose-6-phosphate dehydrogenase
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
An association between favism (a hemolytic reaction to consumption of fava beans), glucose-6-phosphate dehydrogenase deficiency (G6PD(-)) and acid phosphatase locus 1 (ACP(1)) phenotypes has been reported; the frequency of carriers of the p(a) and p(c) ACP(1) alleles was found to be significantly higher in G6PD(-) individuals showing favism than in the general population.
|
21644204 |
2011 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
As well as providing further support to the concept that pituitary stem cells may play an important role in the oncogenesis of human ACP, our data reveal novel disease biomarkers and potential pharmacological targets for the treatment of these devastating childhood tumours.
|
22349813 |
2012 |
|
Favism
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Association between ACP(1) genetic polymorphism and favism.
|
21644204 |
2011 |
|
Hereditary Nonpolyposis Colorectal Cancer
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Because both beta-catenin and ACP gene mutations have recently been shown to activate the same signaling pathway, we analyzed beta-catenin mutation in HNPCC tumors.
|
10493496 |
1999 |
|
Cardiomyopathy, Dilated
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Cardiac-specific deletion of Ndufab1 in mice caused defective bioenergetics and elevated ROS levels, leading to progressive dilated cardiomyopathy and eventual heart failure and sudden death.
|
31366990 |
2019 |
|
Tuberculosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Chemical synthesis and in silico molecular modeling of novel pyrrolyl benzohydrazide derivatives: Their biological evaluation against enoyl ACP reductase (InhA) and Mycobacterium tuberculosis.
|
28961440 |
2017 |
|
Hairy Cell Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Classically, AcPs have been divided into four types according to their sensitivity to tartrate and to their origin: erythrocytic, lysosomal, prostatic AcP, and an AcP enzyme that was first identified in hairy cell leukemia (HCL).
|
8127141 |
1994 |
|
Neurodegenerative Disorders
|
0.010 |
AlteredExpression
|
group |
BEFREE |
CoA-dependent activation of mitochondrial acyl carrier protein links four neurodegenerative diseases.
|
31701655 |
2019 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.
|
28645939 |
2017 |
|
Obesity
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Erythrocyte acid phosphatase (ACP locus 1), also known as low-molecular-weight protein tyrosine phosphatase, has previously been associated to glycemia, dyslipidemia, and obesity.
|
19570551 |
2009 |
|
Benign Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Even though ACP is a benign tumor, treatment is challenging because of the tumor's eloquent location.
|
28414888 |
2017 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Even though ACP is a benign tumor, treatment is challenging because of the tumor's eloquent location.
|
28414888 |
2017 |
|
Presenile dementia
|
0.030 |
Biomarker
|
disease |
BEFREE |
For people with dementia, it is essential to identify the right time to introduce ACP before NH admission.
|
28988561 |
2018 |
|
Dementia
|
0.030 |
Biomarker
|
disease |
BEFREE |
For people with dementia, it is essential to identify the right time to introduce ACP before NH admission.
|
28988561 |
2018 |
|
Lymphoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Here, we evaluated the activity of acalabrutinib (ACP-196) and ACP-319 (AMG-319), second generation inhibitors of Bruton tyrosine kinase (BTK) and PI3Kδ inhibitor, respectively, in lymphoma pre-clinical models.
|
31355927 |
2019 |
|
Adult Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we evaluated the activity of acalabrutinib (ACP-196) and ACP-319 (AMG-319), second generation inhibitors of Bruton tyrosine kinase (BTK) and PI3Kδ inhibitor, respectively, in lymphoma pre-clinical models.
|
31355927 |
2019 |
|
Childhood Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we evaluated the activity of acalabrutinib (ACP-196) and ACP-319 (AMG-319), second generation inhibitors of Bruton tyrosine kinase (BTK) and PI3Kδ inhibitor, respectively, in lymphoma pre-clinical models.
|
31355927 |
2019 |
|
polyps
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Human herpesvirus 6 (HHV-6) was absent in control goup, and positive in ACP middle meatus on affected side was significantly higher than that in ACP polypous surface and ACP polyp group (P < 0.05).
|
31837561 |
2020 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, adults recommended initiation or intensification of antihypertensive medication by the ACC/AHA but not the ACP/AAFP guideline have high atherosclerotic cardiovascular disease risk that may be reduced through treatment initiation or intensification.
|
30595115 |
2019 |
|
Ataxic cerebral palsy
|
0.040 |
Biomarker
|
disease |
BEFREE |
In the absence of FXN, the NFS1-ISD11-ACP (SDA) complex was reportedly inhibited by binding of recombinant ISCU.
|
30031876 |
2018 |
|
Adamantinous Craniopharyngioma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In the absence of FXN, the NFS1-ISD11-ACP (SDA) complex was reportedly inhibited by binding of recombinant ISCU.
|
30031876 |
2018 |